Predicting Outcomes in Sarcoma Herpesvirus-Associated Castleman's Disease
5 Views
administrator
06/15/23
Thomas Uldrick, MD, Staff Clinician at the National Cancer Institute of the National Institutes of Health discusses what baseline measures will help predict outcomes in patients with sarcoma herpesvirus-associated Casteleman's disease.
Source
Uldrick A, Polizzotto MN, Goncalves P, et al. Outcomes in Kaposi sarcoma herpesvirus-‐associated multicentric Castleman disease patients treated with rituximab and liposomal doxorubicin (R-‐Dox). Hematol Oncol. 2015; 33(suppl):201. Presented at: 13th International Conference of Malignant Lymphoma; Lugano, Switzerland; June 17-20, 2015.
-
Category
Show more
Facebook Comments
No comments found